Three startups have recently emerged with plans to edit the epigenome rather than DNA directly. Here’s why that matters and what they aim to do. 

New companies are being built more carefully and platform technologies are less in vouge as the downturn's effects ripple through the private sector.

Biogen will try to enforce patents protecting Tysabri, but an executive last week acknowledged that copycat drugs could launch when approved in the U.S.

The Lilly-backed Rona Therapeutics gains rights to a platform for small interfering RNA, along with a slate of preclinical candidates aimed at targets in the liver and other tissues.

The deal’s near-term effects might not be large, but Amazon’s acquisition still threaten’s One Medical’s primary care competitors and others seeking a greater slice of the market, experts said.

Vaccine maker Bavarian Nordic said it is meeting demand for its shot with production capacity of 30 million doses a year.

The agency agreed to quickly assess the companies’ drug Enhertu for “HER2 low” metastatic breast cancer, an indication for which it could become the first targeted treatment option.

Discover examples of how Droplet Digital™ PCR (ddPCR™) is enabling cell and gene therapies to reach further than ever before. 

The positive decision comes as governments aim to expand supply and quicken distribution of the vaccine to combat a widening global outbreak. Separately, the EMA backed approvals of 11 other medicines.

Trial results released earlier this year showed potential for the drug, which has become one of Vertex’s top pipeline prospects.

The pharma company plans to spend $70 million on the South San Francisco facility, which will house West Coast employees of Astellas Gene Therapies.

The London-based drugmaker is currently seeking a partner to continue development of the hemophilia B treatment, which has shown promise in testing but trails a rival therapy from CSL Behring and UniQure.